Cargando…

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merz, Patrick R., Röckel, Nina, Ballikaya, Seda, Auffarth, Gerd U., Schmack, Ingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288953/ https://www.ncbi.nlm.nih.gov/pubmed/30537942 http://dx.doi.org/10.1186/s12886-018-0978-9

Ejemplares similares

A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
por: Nagpal, Manish, et al.
Publicado: (2007)

Avastin and Lucentis: what do patients know? A prospective questionnaire survey
por: Manna, Avinash, et al.
Publicado: (2013)

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(®))
por: Horowitz, Soraya Alessandra, et al.
Publicado: (2020)

Pharmacokinetics of intravitreal bevacizumab (Avastin(®)) in rabbits
por: Sinapis, Christos I, et al.
Publicado: (2011)

Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar
por: Kim, Eunji, et al.
Publicado: (2022)

Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization
por: Chen, Wei-Li, et al.
Publicado: (2014)

A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment
por: Andric, Marko, et al.
Publicado: (2013)

Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma
por: Mandal, Subrata, et al.
Publicado: (2011)

Using intravitreal bevacizumab (Avastin(®)) – Indian Scenario
por: Kumar, Atul, et al.
Publicado: (2017)

Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration
por: Reis, Gustavo MSM, et al.
Publicado: (2017)

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
por: Ahn, Ye Jin, et al.
Publicado: (2014)

Intravitreal Bevacizumab (Avastin) as an Adjuvant for the Treatment of Posterior Scleritis
por: Lim, Ji Won, et al.
Publicado: (2011)

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
por: Shaikh, Saad
Publicado: (2008)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
por: Scalzo, G C, et al.
Publicado: (2010)

Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks
por: Sachdev, Nishant, et al.
Publicado: (2007)

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
por: Arevalo, J. Fernando, et al.
Publicado: (2011)

Bevacizumab (Avastin(®)) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Brouzas, Dimitrios, et al.
Publicado: (2009)

Intravitreal Bevacizumab (Avastin) as an Adjuvant Treatment in Cases of Neovascular Glaucoma
por: Ghanem, Asaad A., et al.
Publicado: (2009)

Impact of Intravitreal Injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina
por: Karawya, Sherif, et al.
Publicado: (2008)

Intravitreal Bevacizumab (Avastin) as an Adjuvant Therapy for Choroidal Carcinoid Metastasis
por: Karimi, Saeed, et al.
Publicado: (2020)

Endophthalmitis After Intravitreal Bevacizumab (Avastin) Injections: An Outbreak Investigated
por: Shoaib, Khawaja K, et al.
Publicado: (2023)

Implantation of an Artificial Endothelial Layer for Treatment of Chronic Corneal Edema
por: Auffarth, Gerd U., et al.
Publicado: (2021)

Intravitreal Bevacizumab (Avastin) Treatment of Neovascular Glaucoma in Ocular Ischemic Syndrome
por: Lee, Sang Joon, et al.
Publicado: (2009)

Acute Bilateral Endophthalmitis Following Bilateral Intravitreal Bevacizumab (Avastin) Injection
por: Tabatabaii, Ali, et al.
Publicado: (2013)

Experimental analysis of recommended corneal incision sizes in cataract surgery using 13 intraocular lens injector systems
por: Friedrich, Maximilian, et al.
Publicado: (2023)

Effect of bevacizumab (Avastin™) on mitochondrial function of in vitro retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells
por: Luthra, Saurabh, et al.
Publicado: (2013)

The Effect of Bevacizumab versus Ranibizumab in the Treatment of Corneal Neovascularization: A Preliminary Study
por: Kim, Jin-Hyoung, et al.
Publicado: (2013)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017)

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population
por: Kumar, Atul, et al.
Publicado: (2007)

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Gutiérrez, Juan Carlos Mesa, et al.
Publicado: (2008)

Bevacizumab (Avastin) and Thermal Laser Combination Therapy for Peripapillary Choroidal Neovascular Membranes
por: Adrean, Sean D., et al.
Publicado: (2017)

Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario
por: Jain, Prashant, et al.
Publicado: (2017)

Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab
por: Onda, Masahiro, et al.
Publicado: (2019)

Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro
por: Deissler, Heidrun L., et al.
Publicado: (2022)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Lasting Controversy on Ranibizumab and Bevacizumab
por: Zou, Lihui, et al.
Publicado: (2011)

Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences
por: Deissler, Heidrun L, et al.
Publicado: (2012)

Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010)

Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear
por: Wan, Jia, et al.
Publicado: (2012)

The effect of intravitreal bevacizumab (Avastin(®)) on ocular pulse amplitude in neovascular age-related macular degeneration
por: Rechtman, Ehud, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ju8ctvof87f44eic02099irak3